Last reviewed · How we verify
Midazolam and propofol
At a glance
| Generic name | Midazolam and propofol |
|---|---|
| Also known as | Dormicum, Diprivan |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Propofol vs Remifentanil for Sedation in Gastroscopy (NA)
- General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound (NA)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy (PHASE4)
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midazolam and propofol CI brief — competitive landscape report
- Midazolam and propofol updates RSS · CI watch RSS
- Ain Shams University portfolio CI